Nelson Advisors: The ring wants to be your doctor: analysing Oura's $625M Counsel Health acquisition
Oura has spent a decade telling people what their bodies are doing. On Tuesday it paid $625 million for the ability to do something about it.
The smart-ring maker has agreed to buy Counsel Health, an AI-native virtual primary care company, in an all-cash deal expected to close before the end of 2026. Counsel pairs a chat-based medical AI with its own board-certified physicians, who can join a conversation within minutes to diagnose, prescribe and refer. The service already sits inside the Oura app. Now Oura will own it.
On the surface this is a neat product story: the ring spots the problem and the doctor deals with it. Underneath is a more interesting corporate one. Oura shelved a $2.2 billion IPO only weeks ago. It is growing at a rate most hardware companies would find implausible, yet roughly four-fifths of its revenue still comes from selling rings. The Counsel deal is the clearest statement so far of what management wants Oura to be before it tries the public markets again: a healthcare company that happens to make a ring, where today it is a ring company with a subscription attached.
Our article below looks at what Oura is buying, why it is buying now, whether the price stacks up, and where the plan could go wrong. My view in brief: the strategic logic is sound and the price is affordable. But the deal takes Oura out of a business it has mastered and into one where consumer-tech companies have a poor record, and the difficult part is everything that happens after the press release.
The deal at a glance
The headline terms are simple, and Oura chose to publish them alongside a set of record quarterly numbers.
Item | Detail |
Price | $625m in cash, subject to purchase price adjustments |
Expected close | Before the end of calendar 2026, subject to customary conditions |
Target | Counsel Health, founded 2023, about 70 employees |
Counsel funding | $25m Series A in October 2025 led by Andreessen Horowitz and GV; about $36m raised in total, per PitchBook |
Leadership | Founder and CEO Dr Muthu Alagappan becomes Oura's chief clinical AI officer |
Oura fiscal Q4 (Jul to Sep 2026) | Revenue $533m, up 153% year on year; adjusted EBITDA $87m, a 16% margin |
Oura fiscal 2026 (Oct 2025 to Sep 2026) | Revenue of about $1.75bn, up 92% |
Oura members | More than six million |
Oura's last private valuation | $11bn, October 2025 |
Sources: Oura and Counsel announcement, TechCrunch.
Two caveats. Oura's quarterly and full-year figures are preliminary and unaudited. And while the companies' own announcement says the consideration is cash, a couple of outlets described it as cash and stock. I have gone with the announcement.
The two companies are not strangers. Counsel's chatbot was added to the Oura app in June, and Alagappan says the deal was negotiated over the past few months. Oura has, in effect, run a five-month trial of the product with its own members before buying the company behind it.
What Oura is actually buying
Oura is buying three things: a working clinical operation, a clinical AI team, and a route into enterprise healthcare. The chatbot most coverage has focused on is the least scarce of them.
A clinical operation. A member starts by chatting with Counsel's AI, which draws on connected medical records, earlier conversations, clinical guidelines and, for Oura users, continuous biometric data. At any point the member can add a Counsel physician, who can diagnose, prescribe and refer. Counsel employs those doctors itself and does not broker access to someone else's network. On its consumer site the AI conversation is free and adding a doctor costs $29. Building this from scratch means recruiting and credentialing physicians, licensing them state by state, setting up prescribing, arranging malpractice cover and passing compliance audits. That is slow, unglamorous work, and it is the part a consumer hardware company is worst placed to do alone.
A clinical AI stack, and the people who built it. Counsel describes its system as a harness that calls specialised agents for history-taking, guideline retrieval, records review and emergency detection, each evaluated separately and tuned on feedback from its own doctors. On the physician side, a tool it calls the Clinician Cockpit summarises the patient's record and trends and suggests next steps. The design goal is throughput: let the AI do the gathering and drafting so that each doctor can safely handle far more patients than in a conventional telehealth visit. Oura already has an in-app AI adviser, but a wellness coach and a tool that sits inside a clinical decision are different products with different failure costs. Alagappan's new title, chief clinical AI officer, says which of the two Oura wants to get better at.
An enterprise channel. Counsel sells to health plans, health systems, employers and consumer health companies, pitching itself as a replacement for nurse triage lines and conventional telehealth. Oura says Counsel will keep serving those customers after the deal. That matters because it gives Oura a way to reach people who will never buy a ring, and because insurers and employers are who pays for most American healthcare.
There is also some early evidence that the combination works. Oura says more than 90% of surveyed members who used Counsel felt their ring data helped them get better care, and that those who saw a physician rated the experience 4.6 out of 5. Treat those numbers with care. They are company-run surveys of early adopters who opted in to a new feature, which is about as friendly an audience as exists.
Why now: the shelved IPO
The timing makes most sense read against the IPO that did not happen. Oura filed publicly in early September, set terms later that month to sell 50 million shares at $40 to $44 each, and was aiming to raise up to $2.2bn at a fully diluted valuation of about $15.6bn. Within weeks it postponed the offering indefinitely, citing uncertainty in the IPO market.
The prospectus showed a very good business with one awkward feature. In the nine months to 30 June 2026, revenue was $1.21bn, up 74%, and the company made net income of $61m. But $974m of that revenue, about 80%, came from hardware. Membership revenue was $240.5m. It more than doubled year on year and carried an 89% gross margin, yet it was still only a fifth of the total.
That mix is the valuation problem in one line. Public investors pay high multiples for recurring, high-margin revenue and much lower ones for consumer devices, whose sales depend on the next product cycle and the next Christmas. At the top of its range Oura was asking for roughly nine times fiscal 2026 revenue, a software-style multiple for a company whose revenue was mostly rings. Sceptics said so at the time. One IPO academic told Yahoo Finance that valuation was the big concern.
Seen that way, Counsel is an answer to the question the roadshow raised: what else can you sell a member, every month, once they own the ring? Healthcare is the largest possible answer. It also changes the comparison set. A company that delivers primary care, takes reimbursement and sells to health plans gets discussed alongside healthcare platforms, where a pure wearable maker gets discussed alongside Fitbit and Garmin.
Two other things make this the moment. First, Oura can afford it. It raised about $900m a year ago, is profitable, and generated $87m of adjusted EBITDA last quarter alone. Paying cash while private also avoids issuing shares at a price the market has just declined to validate. Second, announcing the deal with a 153% growth quarter is deliberate sequencing. The message to future IPO investors is that postponement was a choice made from strength, and that the capital is being put to work.
There is a defensive reading too. Counsel was a partner with its own enterprise customers and its own ambitions. A partnership can be repriced, ended, or bought out from under you by a rival wearable maker or a health insurer. If the June integration convinced Oura that care was core to its future, leaving the clinical layer in someone else's hands was the riskier option.
Is $625M a fair price?
Measured against Counsel, the price is steep. Measured against Oura, it is small. Both are true, and the second matters more.
Start with Counsel. The company is three years old and has raised about $36m. Its Series A, thirteen months ago, was reported by secondary-market data provider Caplight at an estimated valuation of around $155m. On those figures Oura is paying roughly four times the last round and about seventeen times all the capital ever invested. With around 70 staff, that is close to $9m per employee. Counsel's revenue has not been disclosed, so no revenue multiple can be calculated, and it is reasonable to assume the multiple would be very high. For Andreessen Horowitz, GV and the other backers, this is a fast and handsome exit.
Now look from Oura's side. $625m is under 6% of its last private valuation and about 4% of the valuation it sought at IPO. It is a little more than one quarter's revenue and about seven quarters of adjusted EBITDA at the latest run rate. A company growing 92% a year can absorb that without changing its plans.
A strategic buyer also values a target differently from a financial one. Oura is paying for what Counsel can do when attached to six million paying members, a distribution advantage Counsel could not have built alone. There is a scarcity premium as well. Few companies combine a credible clinical AI system, employed physicians and live enterprise contracts, and one of them was already wired into Oura's app.
Still, the price sets a demanding bar. A rough illustration helps. Spread across six million members, $625m is about $104 each. Suppose 10% of members used a $29 physician consult four times a year. That would bring in about $70m of annual revenue, before paying the doctors. Consult fees alone do not come close to justifying the deal.
The return therefore has to come from elsewhere: higher retention and pricing power on the core membership, new paid care programmes in areas such as weight management and women's health, enterprise contracts, and reimbursement from insurers and public payers. Each is plausible. None is proven at Oura's scale. The fair summary is that Oura has paid a full price for an option on becoming a healthcare company, and can comfortably afford the premium.
The strategic logic: from insight to action
The case for the deal is that a wearable on its own stops at the most valuable moment. The ring can tell you your resting heart rate has crept up, your temperature is elevated or your sleep has fragmented for a fortnight. Then it leaves you to work out what that means and whom to ask. Oura's executive chairman, David Shuman, put the pitch in a sentence: Oura tells members what is happening in their bodies, and Counsel helps them act on it.
Four arguments sit behind that line.
It makes the membership harder to cancel. Sleep and readiness scores are engaging for a few months, and then many users feel they have learned what there is to learn. A doctor who already knows your history is a relationship, and people rarely cancel relationships with their doctor. If care lifts retention by even a few points across six million members, the effect on lifetime value is large, which is exactly the benefit Shuman highlighted.
It opens a bigger wallet. Oura's standard membership costs about $70 a year. A single $29 consult is worth roughly five months of that, and a managed programme for weight loss, fertility or blood pressure is worth far more. Counsel has already launched a GLP-1 weight-management programme, and the companies named reproductive health, ageing and cardiometabolic health as priorities. These are areas where patients pay monthly and stay for years.
The data makes the care better, and the care makes the data matter. A telehealth doctor normally starts with a blank page and a patient's recollection. A Counsel physician sees months of objective trends before the first message. That should mean faster, better-informed consultations, and it gives Counsel's AI a kind of context that general-purpose chatbots lack. In the other direction, clinical outcomes give Oura's algorithms something to learn from beyond wellness scores. A competitor that has only the device or only the clinic would find this loop hard to copy.
It connects Oura to the people who pay for healthcare. Consumers pay for rings. Insurers, employers and governments pay for care. Counsel's enterprise contracts are a way in, and the company is also reported to be taking part in ACCESS, a new Medicare payment model that rewards technology-enabled chronic care providers for measured improvements in patients' health. If continuous monitoring demonstrably improves outcomes in conditions such as hypertension, Oura could be paid for results, with membership fees becoming only one of its income lines. That is a far larger market than selling rings to the health-conscious.
Put together, the ambition is a single continuous service: monitoring that notices a change, an AI that explains it, a doctor who treats it, and the same ring confirming whether the treatment worked. Hale calls it a 24-7 doctor in your pocket. No large company has yet assembled all four parts under one roof.
The risks
The deal's weak points are all in execution, and there are six worth taking seriously.
Care delivery has worse economics than software. Oura's membership revenue carries an 89% gross margin because serving one more subscriber costs almost nothing. Serving one more patient costs a doctor's time. Counsel's whole premise is that AI lets each physician handle many more patients, and the deal's economics depend on that being true at many times its current volume. If demand from six million members arrives faster than efficiency improves, Oura must choose between hiring doctors quickly, which hurts margins, and letting response times slip, which hurts the product.
Oura takes on medical liability and a new set of regulators. Its own press release still carries the line that the ring is not a medical device and is not intended to diagnose or treat anything. That positioning has kept it under lighter-touch wellness rules. Owning a medical practice sits uneasily with it. A missed diagnosis in a chat is now Oura's problem, in court and in the press. Regulators may also ask whether a ring whose readings routinely feed clinical decisions is still just a wellness product. Add state-by-state physician licensing, rules in many US states restricting companies from employing doctors directly, and growing scrutiny of AI in clinical advice, and the compliance burden is of a different order from anything Oura has managed before.
Privacy becomes a sharper issue. Consumer wearable data in the US generally falls outside HIPAA, the health privacy law, while data inside a clinical service falls within it. Members will reasonably ask what moves between the two, who can see it, and whether their sleep and cycle data could reach an employer or insurer through Counsel's enterprise business. Oura has form here: it faced a user backlash in 2025 over its work with the US Department of Defense and Palantir. Trust is the asset this strategy spends, so consent and data separation need to be explicit and easy to understand.
The clinical benefit is not yet proven. Continuous monitoring produces a lot of signals, and most of them are noise. Routing every anomaly to a doctor risks over-investigation, anxious users and a service used mainly by healthy people who need it least. Whether wearable data improves outcomes at population level, and not only satisfaction scores, is still an open research question. Outcome-based payment only pays if the outcomes appear.
The precedents are discouraging. Teladoc paid $18.5bn for Livongo in 2020 to combine virtual care with connected devices, then wrote off most of the value. Walmart closed its health clinics in 2024. Amazon shut its first care service before buying One Medical. In each case a strong consumer or technology franchise found healthcare slower, more regulated and less profitable than expected. Oura's deal is far smaller and starts from a live integration, which helps, but the pattern is hard to ignore.
Counsel now serves two masters, in one country. Health plans and employers bought from an independent vendor. Some may hesitate to send members through a service owned by a consumer brand with its own app to promote, and rival wearable makers certainly will. Meanwhile Counsel's doctors are licensed in the US, and by one report the service currently covers 43 states. Oura's members are global. A flagship benefit that many paying members cannot use is an awkward thing to market.
What it means for the wider industry
The deal raises the stakes for every company that collects health data without acting on it. Whoop, Oura's closest rival, raised $575m at a $10.1bn valuation in March and has pursued healthcare through partnerships. It now has to decide whether partnering is enough. Apple, Samsung and Google have more users and more regulatory clearances than Oura, but none employs doctors.
For AI-native care startups, a $625m exit one year after a Series A resets expectations. It suggests the likeliest buyers are consumer platforms with large engaged audiences and no clinical capability, and that a live integration is the best sales pitch. Expect more wearable, fitness and nutrition apps to trial a care partner and then face the same buy-or-rent decision.
For general-purpose AI chatbots moving into health, the deal marks out a different position. A chatbot can answer a medical question. It cannot write a prescription, and it does not know your overnight heart rate unless you tell it. Oura is betting that the winning product combines continuous data, AI and a licensed human who can act.
What to watch next
Five things will show whether the bet is paying off:
Uptake. What share of members use Counsel, and how many pay for a physician.
Pricing. Whether care is bundled into a pricier membership tier or sold per visit and per programme.
Margins. Whether gross margin holds as physician costs scale with demand.
Enterprise retention. Whether Counsel keeps and wins health-plan and employer contracts under Oura's ownership.
The IPO. Whether Oura returns to market in 2027 with care revenue large enough to change how it is valued.
Oura has bought a credible answer to the question of what comes after the ring. It now has to run a medical practice as well as it runs a hardware business, and the next prospectus will show whether it can.
Sources
Oura to acquire Counsel Health (company announcement, 10 November 2026)
TechCrunch: Oura to acquire AI-native primary care startup Counsel Health for $625M
Fierce Healthcare: Oura to acquire AI virtual primary care partner Counsel Health for $625M
TechRepublic: Oura seeks up to $2.2 billion in IPO at $15.6 billion valuation
Tech Times: Oura pays $625 million to put AI-assisted doctors inside its smart ring app (source for the 43-state figure and ACCESS participation; not independently confirmed)
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments